Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 2:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 3
1 (25.0%)Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Phase 2
Completed
- Conditions
- Covid19Corona Virus Infection
- Interventions
- Diagnostic Test: Biochemistry blood testDiagnostic Test: Hematology blood testDiagnostic Test: D-Dimer test (coagulation)Diagnostic Test: Inflammatory markersDiagnostic Test: Vital signsDiagnostic Test: VAS scaleDiagnostic Test: WHO Ordinal ScoreDiagnostic Test: COVID-19-Related Symptoms assessmentDiagnostic Test: COVID-19-Impact on Quality-of-Life QuestionnaireDiagnostic Test: Pregnancy testDiagnostic Test: Physical examinationDiagnostic Test: PK parametersDiagnostic Test: SARS-CoV-2 test (PCR)Diagnostic Test: ECGDrug: Treatment administration (twice a day)
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- MGC Pharmaceuticals d.o.o
- Target Recruit Count
- 240
- Registration Number
- NCT05037162
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Phase 3
- Conditions
- Corona Virus InfectionCovid19SARS-CoV Infection
- Interventions
- Diagnostic Test: Confirm SARS-CoV-2 infectionDrug: Placebo administrationProcedure: Physical ExaminationProcedure: Vital SignsDiagnostic Test: Hematology blood testDiagnostic Test: Biochemistry blood testOther: NEWS scoreDiagnostic Test: PK testDiagnostic Test: blood test for inflammatory markersDiagnostic Test: D-dimer testOther: VAS scaleDiagnostic Test: Urine pregnancy test for women of childbearing potentialProcedure: ECGOther: COVID-19-Impact on Quality of Life Questionnaire
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- MGC Pharmaceuticals d.o.o
- Target Recruit Count
- 252
- Registration Number
- NCT04802382
- Locations
- 🇮🇱
Nazareth Hospital EMMS, Nazareth, North, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies
Phase 2
Withdrawn
- Conditions
- Children EpilepsyChildren and Adolescents With Resistant EpilepsiesResistant Epilepsy, DrugAdolescent Epilepsy
- Interventions
- Drug: PlaceboDiagnostic Test: ECGDiagnostic Test: EEGDiagnostic Test: Blood and urine collection
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- MGC Pharmaceuticals d.o.o
- Registration Number
- NCT04406948
- Locations
- 🇮🇱
Schneider Children's Medical Center of Israel, Petach Tikvah, Central District, Israel
🇸🇮University Children's Hospital Ljubljana University Medical Centre Ljubljana, Ljubljana, Slovenia
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Phase 2
Completed
- Conditions
- Corona Virus InfectionSARS-CoV 2COVID-19Coronavirus InfectionCoronavirus
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- MGC Pharmaceuticals d.o.o
- Target Recruit Count
- 50
- Registration Number
- NCT04382040
- Locations
- 🇮🇳
Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, Maharashtra, India
🇮🇱Hillel Yaffe Medical Center, Hadera, Haifa, Israel
🇮🇱Nazareth Hospital EMMS, Nazareth, North, Israel
News
No news found